Use of sodium–glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation

BACKGROUND: Sodium–glucose cotransporter 2 (SGLT2) inhibitors have important kidney and cardiovascular benefits in adults with chronic kidney disease. Among adults with diabetes, we characterized the prevalence of chronic kidney disease eligible for SGLT2 inhibitor treatment, based on definitions of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Darren, Pannu, Neesh, Yeung, Roseanne O., Scott-Douglas, Nairne, Klarenbach, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CMA Impact Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894653/
https://www.ncbi.nlm.nih.gov/pubmed/36720493
http://dx.doi.org/10.9778/cmajo.20210281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894653/
https://www.ncbi.nlm.nih.gov/pubmed/36720493
http://dx.doi.org/10.9778/cmajo.20210281

Ejemplares similares